Funds holding PASITHEA THERAPEUTICS CORP
ISIN US70261F2020 · United States
- Fund holders
- 4
- Of which ETFs
- 1 3 other funds
- Value held
- 334K $
- Share of capital
- 1.3 % of 33.4M shares on Aug 12, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| AdvisorShares Psychedelics ETF AdvisorShares Trust | 337,508 | 250.4K $ | 1.24 % | 1.01 % | as of Mar 31, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 53,815 | 39.9K $ | 0.16 % | as of Mar 31, 2026 ↗ | |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 41,608 | 36.7K $ | 0.00 % | 0.12 % | as of Feb 28, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 7,969 | 7K $ | 0.02 % | as of Feb 28, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table counts shares; this one measures what the company weighs inside each fund.
| Fund | Weight in fund | |
|---|---|---|
| AdvisorShares Psychedelics ETF AdvisorShares Trust | 1.24 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
Quarter after quarter
Each SEC quarterly data set, newest first. The change is read against the quarter before it.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 4 | 0 | 440,900 | +15.7 % |
| 2026Q1 | 4 | 0 | 381,219 | +16.3 % |
| 2025Q4 | 4 | +1 | 327,845 | +62.0 % |
| 2025Q3 | 3 | 0 | 202,318 | +252.5 % |
| 2025Q2 | 3 | +1 | 57,391 | +1,393.0 % |
| 2025Q1 | 2 | 0 | 3,844 | -28.4 % |
| 2024Q4 | 2 | 0 | 5,372 | -15.7 % |
| 2024Q3 | 2 | 0 | 6,371 | -0.8 % |
| 2024Q2 | 2 | 6,420 |
Institutional managers
19 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 2,100,000 | 1.6M $ | as of Mar 31, 2026 |
| Vivo Capital, LLC | 2,100,000 | 1.6M $ | as of Mar 31, 2026 |
| Squadron Capital Management LLC | 2,100,000 | 1.6M $ | as of Mar 31, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,100,000 | 1.6M $ | as of Mar 31, 2026 |
| AMERIPRISE FINANCIAL INC | 1,350,896 | 1M $ | as of Mar 31, 2026 |
| Cable Car Capital, LP | 1,206,379 | 894.9K $ | as of Mar 31, 2026 |
| Stonepine Capital Management, LLC | 831,301 | 616.7K $ | as of Mar 31, 2026 |
| AdvisorShares Investments LLC | 337,508 | 250.4K $ | as of Mar 31, 2026 |
| Persistent Asset Partners Ltd | 290,555 | 215.5K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 103,985 | 77.1K $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 93,399 | 69.3K $ | as of Mar 31, 2026 |
| XTX Topco Ltd | 33,751 | 25K $ | as of Mar 31, 2026 |
| UBS Group AG | 26,149 | 19.4K $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 21,054 | 15.6K $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 19,372 | 14.4K $ | as of Mar 31, 2026 |
| Hurley Capital, LLC | 3,689 | 2.7K $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 1,854 | 1.4K $ | as of Mar 31, 2026 |
| SBI Securities Co., Ltd. | 1,051 | 780 $ | as of Mar 31, 2026 |
| JPMORGAN CHASE & CO | 150 | 107 $ | as of Mar 31, 2026 |
Declared shareholders of PASITHEA THERAPEUTICS CORP
4 beneficial ownership filings. These stakes do not add up: an asset manager filing aggregates its own funds, already counted above.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Opaleye Management Inc. and 2 others | 9.99 % | 2,491,000 | as of Apr 1, 2026 · SCHEDULE 13G |
| Funicular Funds, LP and 2 others | 7.40 % | 1,839,512 | as of Apr 15, 2026 · SCHEDULE 13G |
| Stonepine Capital Management, LLC and 3 others | 5.80 % | 1,952,550 | as of Jun 17, 2026 · SCHEDULE 13G |
| Ameriprise Financial, Inc. and 1 other | 5.40 % | 1,350,896 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding PASITHEA THERAPEUTICS CORP". https://titelia.com/en/stocks/pasithea-therapeutics-corp-US70261F2020